Skip to main content
Erschienen in: BMC Ophthalmology 1/2020

Open Access 01.12.2020 | Correspondence

Povidone-iodine pharmacokinetics and study design

verfasst von: Jagger Koerner, Andrzej Grzybowski

Erschienen in: BMC Ophthalmology | Ausgabe 1/2020

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Dr. Gnanasekaran et al. reported the bactericidal activity of various concentrations of povidone iodine (PI) solution in an agar plate experiment of respiratory flora. The study design and the pharmacokinetic properties of PI solution ensured that dilute PI would not be effective in this study. These results may not replicate the typical clinical situation and are significantly different than a previously reported agar plate experiment, again owing to subtle but very significant differences in methodology.
Hinweise
An author's reply to this comment is available online at https://​doi.​org/​10.​1186/​s12886-020-01599-3.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PI
Povidone iodine

Main text

We read with interest the study by Gnanasekaran et al., and would like to further discuss its methods and a similar agar plate in vitro study conducted by Silas et al. Gnanasekaran and colleagues exposed blood-agar plates to various concentrations of povidone iodine (PI), decanted excess fluid, waited 30 s and then loaded the plates with respiratory flora [1]. This is very different from loading the plates with bacteria and then applying PI solution.
Silas et al. found that by applying PI to blood agar plates already loaded with bacteria, 10, 5 and 2.5% PI eradicated all bacteria [2]. Applying 1% PI three times separated by 2 min produced similar results to 5% PI applied once. The differences between these two agar plate studies are the result of the timing of PI application; before or after the bacteria are loaded onto the plate. They also illustrate a contrast with liquid media-based studies, in which dilute PI solution can eradicate high concentrations of virulent bacteria in 15–30 s [3].
The pharmacokinetic properties of PI solution explain these findings; specifically, the reduction of bactericidal free iodine to iodide species after interaction with organic substances. Dilute PI solution has less total available iodine and therefore becomes “spent” or depleted earlier than more concentrated solutions [4].
Bearing this in mind, therefore, it is not surprising that the 1% PI solution did not inhibit bacterial growth at all; its limited free iodine was exhausted well before the lengthy bacterial loading process was complete. The conclusion “ophthalmologists should avoid diluting PI to concentrations lower than 5% for pre-injection antisepsis” is supported by this article only if usual practice consists of applying PI and then contaminating the site for 5 min. In contrast, if the eye is considered “dirty” prior to antisepsis, PI solution applied, and then the site kept clean for 30 s prior to injection, the results of this study are not applicable. In fact, 1% PI solution applied several times prior to injection can produce excellent antisepsis as shown by Silas et al.
Unfortunately, there is no standardized reliable way to simulate the ocular surface to better study this and related topics in vitro. Applying PI solution after bacteria are loaded onto the plates and waiting 30 sec for the solution to work could better simulate the situation in clinic, especially if typical precautions such as not talking and mask wearing are taken.

Acknowledgements

None.
Not applicable.
Not applicable.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Gnanasekaran S, Rogers S, Wickremasinghe S, Sandhu SS. The effect of diluting povidone-iodine on bacterial growth associated with speech. BMC Ophthalmol. 2019;19(1):62.PubMedPubMedCentralCrossRef Gnanasekaran S, Rogers S, Wickremasinghe S, Sandhu SS. The effect of diluting povidone-iodine on bacterial growth associated with speech. BMC Ophthalmol. 2019;19(1):62.PubMedPubMedCentralCrossRef
2.
Zurück zum Zitat Silas MR, Schroeder RM, Thomson RB, Myers WG. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0. J Cataract Refract Surg. 2017;43(3):400–4.PubMedCrossRef Silas MR, Schroeder RM, Thomson RB, Myers WG. Optimizing the antisepsis protocol: effectiveness of 3 povidone-iodine 1.0% applications versus a single application of povidone-iodine 5.0. J Cataract Refract Surg. 2017;43(3):400–4.PubMedCrossRef
3.
Zurück zum Zitat Koerner JC, George MJ, Kissam EA, Rosco MG. Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates. Digit J Ophthalmol. 2018;24(4):24–6 Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates.PubMedPubMedCentralCrossRef Koerner JC, George MJ, Kissam EA, Rosco MG. Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates. Digit J Ophthalmol. 2018;24(4):24–6 Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates.PubMedPubMedCentralCrossRef
4.
Zurück zum Zitat Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29(1):19–32.PubMedCrossRef Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29(1):19–32.PubMedCrossRef
Metadaten
Titel
Povidone-iodine pharmacokinetics and study design
verfasst von
Jagger Koerner
Andrzej Grzybowski
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Ophthalmology / Ausgabe 1/2020
Elektronische ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-020-1313-9

Weitere Artikel der Ausgabe 1/2020

BMC Ophthalmology 1/2020 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Die Verwendung von Ophthalmika in der Schwangerschaft und Stillzeit stellt immer eine Off-label-Anwendung dar. Ein Einsatz von Arzneimitteln muss daher besonders sorgfältig auf sein Risiko-Nutzen-Verhältnis bewertet werden. In der vorliegenden …

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Vitrektomie Originalie

Die endogene Endophthalmitis ist eine hämatogen fortgeleitete, bakterielle oder fungale Infektion, die über choroidale oder retinale Gefäße in den Augapfel eingeschwemmt wird [ 1 – 3 ]. Von dort infiltrieren die Keime in die Netzhaut, den …

Bakterielle endogene Endophthalmitis

Vitrektomie Leitthema

Eine endogene Endophthalmitis stellt einen ophthalmologischen Notfall dar, der umgehender Diagnostik und Therapie bedarf. Es sollte mit geeigneten Methoden, wie beispielsweise dem Freiburger Endophthalmitis-Set, ein Keimnachweis erfolgen. Bei der …

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Die bestmögliche Wundheilung der Kornea, insbesondere ohne die Ausbildung von lichtstreuenden Narben, ist oberstes Gebot, um einer dauerhaften Schädigung der Hornhaut frühzeitig entgegenzuwirken und die Funktion des Auges zu erhalten.   

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.